Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board

Core Insights - Incannex Healthcare Inc. has expanded its Clinical Advisory Board (CAB) by appointing three new members to enhance the clinical and scientific guidance for the PSX-001 program [1][2][3] Group 1: Clinical Advisory Board Expansion - The newly appointed members are Dr. Murray B. Stein, Dr. Andrew Cutler, and Dr. Amir Kalali, who bring extensive expertise in psychiatry, neurobiology, and clinical development [2][3] - The CAB will provide advice on clinical trial design, endpoint selection, regulatory engagement, and overall development strategy for PSX-001 [2] Group 2: Expertise of New Members - Dr. Murray B. Stein is a Distinguished Professor at UCSD with over 800 peer-reviewed publications and extensive experience in anxiety and trauma-related disorders [4] - Dr. Andrew Cutler is a Clinical Professor with a focus on clinical psychopharmacology and has served as a principal investigator in numerous clinical trials [5] - Dr. Amir Kalali is recognized for his work at the intersection of life sciences and technology, serving as a board director and advisor to various life sciences companies [6][7] Group 3: Company Overview - Incannex Healthcare is focused on developing combination medicines targeting chronic conditions such as obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder [8] - The company is advancing three clinical-stage product candidates, including PSX-001, which is an oral synthetic psilocybin treatment for generalized anxiety disorder [8]